AMICUS THERAPEUTICS INC(NASDAQ:FOLD) stock Fundamental Analysis

Fundamental Rating

We assign a fundamental rating of 4 out of 10 to FOLD. FOLD was compared to 568 industry peers in the Biotechnology industry. There are concerns on the financial health of FOLD while its profitability can be described as average. FOLD shows excellent growth, but is valued quite expensive already.

Quickly go to:

1. Profitability

1.1 Basic Checks

FOLD had negative earnings in the past year.

FOLD had a negative operating cash flow in the past year.

FOLD had negative earnings in each of the past 5 years.

FOLD had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

The Return On Assets of FOLD (-7.15%) is better than 87.85% of its industry peers.

FOLD has a Return On Equity of -28.91%. This is in the better half of the industry: FOLD outperforms 78.87% of its industry peers.

FOLD has a better Return On Invested Capital (4.23%) than 93.49% of its industry peers.

		Industry Rank	Sector Rank
ROA	-7.15%
ROE	-28.91%
ROIC	4.23%

ROA(3y)-19.77%

ROA(5y)-23.64%

ROE(3y)-105.3%

ROE(5y)-98.82%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

FOLD's Operating Margin of 6.45% is amongst the best of the industry. FOLD outperforms 93.49% of its industry peers.

FOLD has a better Gross Margin (89.98%) than 91.20% of its industry peers.

In the last couple of years the Gross Margin of FOLD has remained more or less at the same level.

		Industry Rank	Sector Rank
OM	6.45%
PM (TTM)	N/A
GM	89.98%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y0.48%

GM growth 5Y0.45%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), FOLD is destroying value.

FOLD has more shares outstanding than it did 1 year ago.

FOLD has more shares outstanding than it did 5 years ago.

The debt/assets ratio for FOLD has been reduced compared to a year ago.

2.2 Solvency

FOLD has an Altman-Z score of -1.31. This is a bad value and indicates that FOLD is not financially healthy and even has some risk of bankruptcy.

FOLD has a Altman-Z score (-1.31) which is comparable to the rest of the industry.

FOLD has a Debt/Equity ratio of 2.01. This is a high value indicating a heavy dependency on external financing.

FOLD has a Debt to Equity ratio of 2.01. This is amonst the worse of the industry: FOLD underperforms 81.16% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	2.01
Debt/FCF	N/A
Altman-Z	-1.31

ROIC/WACC0.38

WACC11.25%

2.3 Liquidity

FOLD has a Current Ratio of 3.39. This indicates that FOLD is financially healthy and has no problem in meeting its short term obligations.

FOLD has a worse Current ratio (3.39) than 60.92% of its industry peers.

A Quick Ratio of 2.60 indicates that FOLD has no problem at all paying its short term obligations.

FOLD's Quick ratio of 2.60 is on the low side compared to the rest of the industry. FOLD is outperformed by 68.31% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	3.39
Quick Ratio	2.6

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

FOLD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 64.71%, which is quite impressive.

Looking at the last year, FOLD shows a very strong growth in Revenue. The Revenue has grown by 32.28%.

The Revenue has been growing by 23.73% on average over the past years. This is a very strong growth!

EPS 1Y (TTM)64.71%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%145.45%

Revenue 1Y (TTM)32.28%

Revenue growth 3Y20.03%

Revenue growth 5Y23.73%

Sales Q2Q%30.09%

3.2 Future

FOLD is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 77.43% yearly.

The Revenue is expected to grow by 20.68% on average over the next years. This is a very strong growth

EPS Next Y118.26%

EPS Next 2Y95.6%

EPS Next 3Y83.76%

EPS Next 5Y77.43%

Revenue Next Year19.74%

Revenue Next 2Y20.94%

Revenue Next 3Y21.3%

Revenue Next 5Y20.68%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

FOLD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

The Price/Forward Earnings ratio is 219.08, which means the current valuation is very expensive for FOLD.

Compared to the rest of the industry, the Price/Forward Earnings ratio of FOLD indicates a rather cheap valuation: FOLD is cheaper than 90.49% of the companies listed in the same industry.

The average S&P500 Price/Forward Earnings ratio is at 21.65. FOLD is valued rather expensively when compared to this.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	219.08

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, FOLD is valued cheaply inside the industry as 92.43% of the companies are valued more expensively.

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	53.63

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates FOLD does not grow enough to justify the current Price/Earnings ratio.

A more expensive valuation may be justified as FOLD's earnings are expected to grow with 83.76% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y95.6%

EPS Next 3Y83.76%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for FOLD!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

AMICUS THERAPEUTICS INC

NASDAQ:FOLD (4/24/2025, 8:10:49 PM)

After market: 7.2 0 (0%)

7.2

+0.1 (+1.41%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)02-19 2025-02-19/bmo

Earnings (Next)05-07 2025-05-07/bmo

Inst Owners94.04%

Inst Owner Change0.01%

Ins Owners0.7%

Ins Owner Change12.82%

Market Cap2.21B

Analysts82.22

Price Target17.14 (138.06%)

Short Float %5.6%

Short Ratio6.7

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)1

Avg Revenue beat(2)0.84%

Min Revenue beat(2)-0.84%

Max Revenue beat(2)2.52%

Revenue beat(4)2

Avg Revenue beat(4)0.36%

Min Revenue beat(4)-2.65%

Max Revenue beat(4)2.52%

Revenue beat(8)5

Avg Revenue beat(8)0.64%

Revenue beat(12)7

Avg Revenue beat(12)-0.63%

Revenue beat(16)8

Avg Revenue beat(16)-1.2%

PT rev (1m)2.16%

PT rev (3m)-3.08%

EPS NQ rev (1m)0%

EPS NQ rev (3m)-1764.69%

EPS NY rev (1m)-71.85%

EPS NY rev (3m)-77.93%

Revenue NQ rev (1m)-0.2%

Revenue NQ rev (3m)-3.98%

Revenue NY rev (1m)-0.07%

Revenue NY rev (3m)-1.41%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	219.08
P/S	4.19
P/FCF	N/A
P/OCF	N/A
P/B	11.4
P/tB	N/A
EV/EBITDA	53.63

EPS(TTM)-0.18

EYN/A

EPS(NY)0.03

Fwd EY0.46%

FCF(TTM)-0.12

FCFYN/A

OCF(TTM)-0.11

OCFYN/A

SpS1.72

BVpS0.63

TBVpS-0.07

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-7.15%
ROE	-28.91%
ROCE	5.35%
ROIC	4.23%
ROICexc	6.96%
ROICexgc	15.7%
OM	6.45%
PM (TTM)	N/A
GM	89.98%
FCFM	N/A

ROA(3y)-19.77%

ROA(5y)-23.64%

ROE(3y)-105.3%

ROE(5y)-98.82%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y0.48%

GM growth 5Y0.45%

F-Score5

Asset Turnover0.67

Health

		Industry Rank	Sector Rank
Debt/Equity	2.01
Debt/FCF	N/A
Debt/EBITDA	9.16
Cap/Depr	41.57%
Cap/Sales	0.67%
Interest Coverage	0.58
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	3.39
Quick Ratio	2.6
Altman-Z	-1.31

F-Score5

WACC11.25%

ROIC/WACC0.38

Cap/Depr(3y)68.89%

Cap/Depr(5y)61.13%

Cap/Sales(3y)1.23%

Cap/Sales(5y)1.24%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)64.71%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%145.45%

EPS Next Y118.26%

EPS Next 2Y95.6%

EPS Next 3Y83.76%

EPS Next 5Y77.43%

Revenue 1Y (TTM)32.28%

Revenue growth 3Y20.03%

Revenue growth 5Y23.73%

Sales Q2Q%30.09%

Revenue Next Year19.74%

Revenue Next 2Y20.94%

Revenue Next 3Y21.3%

Revenue Next 5Y20.68%

EBIT growth 1Y144.77%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year195.67%

EBIT Next 3Y119.1%

EBIT Next 5YN/A

FCF growth 1Y51.07%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y50.95%

OCF growth 3YN/A

OCF growth 5YN/A

AMICUS THERAPEUTICS INC (FOLD) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens